Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality
Keywords:
5α-Reductase Inhibitors, Prostate Cancer MortalityAbstract
Background: The role of 5α-reductase inhibitors (5-ARIs) in managing prostate cancer has been a subject of considerable debate within the medical community. The exploration of these agents has evolved significantly over the years, reflecting both their therapeutic potential and the complexities associated with their use. Literature Review: The reviewed literature presents a multifaceted examination of 5α-reductase inhibitors (5-ARIs) and their implications for prostate cancer management. The introduction establishes a framework for understanding the evolving role of these agents, emphasizing both their potential therapeutic benefits and the concerns that have emerged regarding their use, particularly in relation to prostate cancer risk and mortality. Conclusion: In conclusion, the literature collectively indicates that while 5-ARIs possess therapeutic potential in managing prostate cancer, significant concerns regarding their safety profiles—particularly their association with high-grade tumors and implications for mortality—necessitate a cautious and informed approach in clinical practice. Future research should aim to elucidate the complexities of 5-ARIs, focusing on their integration with existing treatment protocols and the need for individualized patient care.
References
J Hudak, S., Hernandez, J., & M Thompson, I., 2006. Role of 5 alpha-reductase inhibitors in the management of prostate cancer. ncbi.nlm.nih.gov
J Hamilton, R. & J Freedland, S., 2011. 5-α reductase inhibitors and prostate cancer prevention: where do we turn now?. ncbi.nlm.nih.gov
Moroz, A., K. Delella, F., Almeida, R., Maria Lacorte, L., José Fávaro, W., Deffune, E., & L. Felisbino, S., 2013. Finasteride Inhibits Human Prostate Cancer Cell Invasion through MMP2 and MMP9 Downregulation. ncbi.nlm.nih.gov
Robinson, D., Garmo, H., Holmberg, L., & Stattin, P., 2015. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer. ncbi.nlm.nih.gov
Wang, J., Zhao, S., Luo, L., Li, E., Li, X., & Zhao, Z. G., 2018. 5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis. ncbi.nlm.nih.gov
Kumar, A., Nalawade, V., Riviere, P., R. Sarkar, R., Kellog Parsons, J., D. Murphy, J., & S. Rose, B., 2019. Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults. ncbi.nlm.nih.gov
Hyun Pyun, J., Son, N. H., Hwii Ko, Y., Won Kim, S., Kim, H., & Bae, Y. J., 2024. The Long-Term Impact of 5-alpha Reductase Inhibitors on the Development of Bladder Cancer and the Need for Radical Cystectomy: A Nationwide Observational Study. ncbi.nlm.nih.gov
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Endah Lestari, Nur Fitriani (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
